Corrigendum: Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma (Oncogene (2013) 33 (2577-2588) DOI: 10.1038/onc.2013.237);Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma

Oncogene

Volumn 33, Issue 20, 2014, Pages 2577-2588

  Jiang, C C ^a   Croft, A ^a,b   Tseng, H Y ^a   Guo, S T ^c   Jin, L ^d   Hersey, P ^d   Zhang, X D ^a,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^c SHANXI CANCER HOSPITAL   (China)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

eIF4E; melanoma; miR 768 3p; mRNA translation; RAF MEK ERK

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ARGONAUTE PROTEIN; INITIATION FACTOR 4E; MICRORNA; MICRORNA 221; MICRORNA 768 3P; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; SMALL NUCLEOLAR RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; METASTATIC MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA INTERFERENCE; RNA TRANSLATION;

EUKARYOTA;

CELL LINE, TUMOR; DOWN-REGULATION; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICRORNAS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84901191625     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.144     Document Type: Erratum

References (54)

1. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010; 10: 254-266
2. Bilanges B, Stokoe D. Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene 2007; 26: 5973-5990. (Pubitemid 47373810
3. Grzmil M, Hemmings BA. Translation regulation as a therapeutic target in cancer. Cancer Res 2012; 72: 3891-3900
4. Bitterman PB, Polunovsky VA. Translational control of cell fate: From integration of environmental signals to breaching anticancer defense. Cell Cycle 2012; 11: 1097-1107
5. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell 2009; 136: 731-745
6. Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 2010; 11: 113-127
7. Phillips A, Blaydes JP. MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA. Oncogene 2008; 27: 1645-1649. (Pubitemid 351347869
8. Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget 2012; 3: 118-131
9. Stumpf CR, Ruggero D. The cancerous translation apparatus. Curr Opin Genet Dev 2011; 21: 474-483
10. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21: 3232-3237. (Pubitemid 350277750
11. Rosenwald IB. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 2004; 23: 3230-3247. (Pubitemid 38638835
12. Larsson O, Li S, Issaenko OA, Avdulov S, Peterson M, Smith K et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 2007; 67: 6814-6824. (Pubitemid 47105529
13. Yang SX, Hewitt SM, Steinberg SM, Liewehr DJ, Swain SM. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-Tumor tissue microarray. Oncol Rep 2007; 17: 281-287
14. Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM, Honarpisheh H et al. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 2009; 100: 1393-1399
15. De Benedetti A, Graff Jr. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23: 3189-3199. (Pubitemid 38638830
16. He L, Hannon GJ 2004MicroRNAs: Small RNAs with a big role in gene regulation Nat Rev Genet 2004; 5: 522-531. (Pubitemid 38868508
17. Iorio MV, Croce CM. MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-5856
18. Humphreys DT, Westman BJ, Martin DI, Preiss T. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci USA 2005; 102: 16961-16966. (Pubitemid 41692666
19. Mathonnet G, Fabian MR, Svitkin YV, Parsyan A, Huck L, Murata T et al. MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science 2007; 317: 1764-1767. (Pubitemid 47461843
20. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482: 347-355
21. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68: 2745-2754. (Pubitemid 351556272
22. Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P et al. MicroRNA-149., a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci USA 2011; 108: 15840-15845
23. Bonazzi VF, Stark MS, Hayward NK. MicroRNA regulation of melanoma progression. Melanoma Res 2012; 22: 101-113
24. Mueller DW, Bosserhoff AK. The evolving concept of 'melano-miRs'- microRNAs in melanomagenesis. Pigment Cell Melanoma Res 2010; 23: 620-626
25. Wilmott JS, Zhang XD, Hersey P, Scolyer RA. The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology 2011; 43: 657-671
26. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714
27. Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY et al. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 2012; 32: 1910-1920
28. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871
29. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1: 395-405
30. Couts KL, Anderson EM, Gross MM, Sullivan K, Ahn NG. Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene 2012; 32: 1959-1970
31. Caramuta S, Egyházi S, Rodolfo M, Witten D, Hansson J, Larsson C et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010; 130: 2062-2070
32. Yanagiya A, Suyama E, Adachi H, Svitkin YV, Aza-Blanc P, Imataka H et al. Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol Cell 2012; 46: 847-858
33. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007; 128: 257-267. (Pubitemid 46137991
34. Valleron W, Ysebaert L, Berquet L, Fataccioli V, Quelen C, Martin A et al. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. Blood 2012; 120: 3997-4005
35. Miyoshi K, Miyoshi T, Siomi H. Many ways to generate microRNA-like small RNAs: Non-canonical pathways for microRNA production. Mol Genet Genom 2010; 284: 95-103
36. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008
37. Kiss T. Biogenesis of small nuclear RNPs. J Cell Sci 2004; 117: 5949-5951. (Pubitemid 40123960
38. Rosenwald IB, Rhoads DB, Callanan LD, Isselbacher KJ, Schmidt EV. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc Natl Acad Sci USA 1993; 90: 6175-6178. (Pubitemid 23191477
39. Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One 2007; 2: E242
40. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993; 13: 7358-7363. (Pubitemid 23354259
41. Koromilas AE, Lazaris-Karatzas A, Sonenberg N. mRNAs containing extensive secondary structure in their 50 non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J 1992; 11: 4153-4158
42. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 50 cap. Nature 1990; 345: 544-547
43. Lazaris-Karatzas A, Sonenberg N. The mRNA 50 cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol Cell Biol 1992; 12: 1234-1238
44. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008; 68: 631-634. (Pubitemid 351206735
45. Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG et al. MicroRNA-137 targets microphthalmia-Associated transcription factor in melanoma cell lines. Cancer Res 2008; 68: 1362-1368. (Pubitemid 351346843
46. Haflidadó ttir BS, Bergsteinsdóttir K, Praetorius C, Steingrí;msson E. miR-148 regulates Mitf in melanoma cells. PLoS One 2010; 5: E11574
47. Li SC, Tang P, Lin WC. Intronic MicroRNA: Discovery and biological implications. DNA Cell Biol 2007; 26: 195-207
48. Takatsu H, Sakurai M, Shin HW, Murakami K, Nakayama K. Identification and characterization of novel clathrin adaptor-related proteins. J Biol Chem 1998; 273: 24693-24700. (Pubitemid 28454969
49. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 2011; 17: 6582-6591
50. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011; 71: 5214-5224
51. Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis 2010; 2: 1:e69
52. Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H et al. Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 2011; 30: 3716-3726
53. Blais JD, Filipenko V, Bi M, Harding HP, Ron D, Koumenis C et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol2004; 24: 7469-7482
54. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F et al. MicroRNAs in renal cell carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS One 2011; 6: E25787